Published in
Massachusetts Medical Society, New England Journal of Medicine, 8(362), p. 697-706
Links
- ORCID
- ORCID
- ORCID
- Massachusetts Medical Society
- [www.ncbi.nlm.nih.gov] | PDF
- [hdl.handle.net]
- [www.ncbi.nlm.nih.gov] | PDF
- [europepmc.org] | PDF
- [www.researchgate.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [citeseerx.ist.psu.edu] | PDF
Tools
Timing of Initiation of Antiretroviral Drugs during Tuberculosis Therapy
Journal article published in 2010 by
Salim S. Abdool Karim 
,
Kogieleum Naidoo,
Anneke C. Grobler ,
Nesri Padayatchi,
Cheryl Baxter ,
Andrew L. Gray,
Tanuja N. Gengiah,
Gonasagrie Nair,
Sheila Bamber,
Aarthi Singh,
Munira Khan,
Jacqueline Pienaar,
Wafaa Mahmoud El-Sadr,
Gerald Friedland,
Quarraisha Abdool Karim
and other authors.
,
Kogieleum Naidoo,
Anneke C. Grobler ,
Nesri Padayatchi,
Cheryl Baxter ,
Andrew L. Gray,
Tanuja N. Gengiah,
Gonasagrie Nair,
Sheila Bamber,
Aarthi Singh,
Munira Khan,
Jacqueline Pienaar,
Wafaa Mahmoud El-Sadr,
Gerald Friedland,
Quarraisha Abdool Karim
and other authors.
This paper is available in a repository.
Full text: Download
Data provided by 
Abstract
The rates of death are high among patients with coinfection with tuberculosis and the human immunodeficiency virus (HIV). The optimal timing for the initiation of antiretroviral therapy in relation to tuberculosis therapy remains controversial.